Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMR4396 dose-response study for chemotherapy-associated anaemia
ISRCTN62713985Phase 3Completed
- Sponsor
- Hoechst Marion Roussel (Shire Pharmaceuticals) (France)
- Start
- May 2000
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of epoetin delta in anaemia (3 arms), sponsored by Hoechst Marion Roussel (Shire Pharmaceuticals) (France). Primary endpoints: Change in haemoglobin from baseline to week 12 and Red blood cell transfusion occurrence during weeks 5 to 12. Started May 2000; status: completed.
02
Drugs
epoetin delta
03
Conditions
anaemia
Beyond the preview
Go deeper on ISRCTN62713985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62713985.